COVID-19 Genomics UK Consortium
The current COVID-19 pandemic, caused by the SARS-CoV-2 virus, represents a major threat to health. The COVID-19 Genomics UK (COG-UK) consortium has been created to deliver large-scale and rapid whole-genome virus sequencing to local NHS centres and the UK government.
COG-UK is made up of an innovative partnership of NHS organisations, the four Public Health Agencies of the UK, the Wellcome Sanger Institute and over twelve academic partners providing sequencing and analysis capacity.
COG-UK is supported by £20 million funding from the UK Department of Health and Social Care (DHSC), UK Research and Innovation (UKRI) and the Wellcome Sanger Institute, administered by UK Research and Innovation.
News and Blogs
Asymptomatic screening and genome sequencing help Cambridge understand spread of SARS-CoV-2 among its students
Since the start of the academic year in October 2020, the University of Cambridge has been offering regular SARS-CoV-2 tests to all students living in its Colleges, even if they show no symptoms. Initial results suggest that the screening programme, together with the University’s public health measures and responsible student behaviour, has helped limit the spread of the virus.
‘World-class’ CLIMB project receives £1.2 million funding boost from UKRI
As part of a wider £213 million investment to expand and upgrade ‘world-class’ research infrastructure, the Cloud Infrastructure for Microbial Bioinformatics (CLIMB) project — the ultra-high performance computing infrastructure which has supported the COVID-19 Genomics UK (COG-UK) consortium throughout the pandemic — has received a £1.2 million funding boost from UK Research and Innovation (UKRI).